Postpartum Depression Market Analysis, Size, Share & Growth Forecast 2026–2034

Zuranolone Zurzuvae Oral 14-Day LANDSCAPE Phase III HAMD17 Improvement Within 3 Days Has Established the First Oral PPD-Specific Treatment With Rapid Antidepressant Onset That Eliminates the 60-Hour Continuous IV Hospitalisation That Brexanolone Zulresso Requires.Sage Therapeutics and Biogen's zuranolone Zurzuvae demonstrated 49.2% response rate versus 28.4% for placebo at day 15 in the ROBIN Phase 3 postpartum depression trial, and the 50 mg oral dose achieving HAMD-17 reduction within 3 days addresses the urgent need for rapid symptom onset in a condition where infant care responsibilities create functional impairment that weekly SSRI onset cannot address quickly enough. The approval for postpartum depression alongside concurrent MDD approval establishes zuranolone as addressing the hormonal neurosteroid withdrawal theory of PPD through positive allosteric GABA-A modulation that restores the GABAergic tone that drops precipitously at delivery with progesterone withdrawal. The 14-day treatment course creates a clinically intuitive acute episode treatment model that obstetricians and midwives can initiate in primary care settings without the psychiatric specialist involvement that IV brexanolone's REMS-required in-patient administration mandate.

Brexanolone Zulresso GABA-A Allopregnanolone Analogue 75 Versus 29 Percent PPD Remission at 60 Hours From IV Infusion Has Established the Neurosteroid Mechanism Reversing the Postpartum Allopregnanolone Withdrawal as the Pathophysiology-Targeting PPD Treatment.Sage Therapeutics's brexanolone Zulresso became the first FDA-approved PPD treatment in March 2019 through a postpartum-specific indication that required continuous 60-hour intravenous infusion in a certified healthcare setting with monitoring for excessive sedation, establishing the neuroactive steroid allopregnanolone as a validated pharmacological target for peripartum mood disorder. The REMS-required hospital or inpatient setting administration limits Zulresso to patients with access to certified treatment facilities, and the 60-hour infusion burden creates a significant childcare coordination challenge that has restricted commercial adoption to academic medical centres and large obstetric systems with programme infrastructure. Brexanolone's pivotal role in validating the neurosteroid mechanism enabled zuranolone's faster development by establishing the regulatory precedent for GABA-A PAM activity as the mechanistic basis for PPD treatment approval.

Edinburgh Postnatal Depression Scale Above 10 at 6-Week Postpartum USPSTF and ACOG Screening Identifying 10 to 15 Percent of New Mothers With Clinically Significant PPD Has Established the Universal Postpartum Screening as the Detection Gateway That Enables the Early Treatment Intervention.The Edinburgh Postnatal Depression Scale screening at 6 and 12 weeks postpartum is mandated by AAP and ACOG guidelines, but approximately 50% of women screening positive for PPD do not receive guideline-directed treatment due to stigma, childcare barriers, and mental health provider shortages that are particularly severe in rural and underserved communities. Postpartum Support International's Provider Training and the MGH Centre for Women's Mental Health telehealth programme have demonstrated that remote CBT-I and CBT-based psychological support delivered by trained therapists can achieve equivalent outcomes to in-person PPD treatment with substantially higher patient participation rates. The integration of PPD screening and digital mental health referral into obstetric electronic medical record systems from Epic and Athena enables systematic identification and automated care pathway activation that addresses the fragmentation between screening and treatment that leaves the majority of EPDS-positive women without appropriate follow-up.

For related market intelligence, see the Depression Drug Market.